1,380 assets in Cancer

Therapeutic assets addressing Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
ly4101174 Cancer	Eli Lilly and Company	P1	CC (43)
Mutant Kras G12V-Specific Tcr Transduced Autologous T Cells Cancer	Changhai Hospital	P1/2	CC (43)
Orm-6151 Cancer	Bristol-Myers Squibb	P1	CC (43)
Osemitamab Cancer	Suzhou Transcenta Therapeutics Co., Ltd.	P1/2	CC (43)
pf-07799544 Cancer	Pfizer	P1	CC (43)
pm534 Cancer	PharmaMar	P1	CC (43)
Polyphenol Whole Tumor Cell Vaccine Cancer	Xingchen Peng	P1	CC (43)
q901 Cancer	Qurient Co., Ltd.	P1/2	CC (43)
Recombinant Fully Human Igg1 Kappa Anti-Tigit Monoclonal Antibody Eos-448 Cancer	iTeos Belgium SA	P1/2	CC (43)
Recombinant Humanized Monoclonal Antibody Mil95 Cancer	Beijing Mabworks Biotech Co., Ltd.	P1	CC (43)
Renvastinib Cancer	Shanghai Junshi Bioscience Co., Ltd.	P1	CC (43)
ro7617991 Cancer	Genentech, Inc.	P1	CC (43)
SAR443216 Cancer	Sanofi	P1	CC (43)
Shr-4602 Cancer	Shanghai Hengrui Pharmaceutical Co., Ltd.	P2	CC (43)
skb571 Cancer	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	P1	CC (43)
Ssgj-612 Cancer	Shenyang Sunshine Pharmaceutical Co., LTD.	P1	CC (43)
TH19P01-DOCETAXEL Cancer	Theratechnologies	P1	CC (43)
Thymosins Thymalfasin Cancer	Second Affiliated Hospital of Soochow University	P2	CC (43)
tqb3915 tablets Cancer	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P1	CC (43)
tt-816 Cancer	Teon Therapeutics, Inc.	P1/2	CC (43)
Tuvusertib Cancer	EMD Serono Research & Development Institute, Inc.	P1	CC (43)
ui-102 Cancer	United Immunity, co., Ltd.	P1/2	CC (43)
Vabametkib Cancer	Abion Inc	P2	CC (43)
ymn101 Cancer	West China Hospital	P1	CC (43)
ymn102 Cancer	West China Hospital	P1	CC (43)
ymn103 Cancer	West China Hospital	P1	CC (43)
ymn104 Cancer	West China Hospital	P1	CC (43)
ymn105 Cancer	West China Hospital	P1	CC (43)
ymn106 Cancer	West China Hospital	P1	CC (43)
ymn107 Cancer	West China Hospital	P1	CC (43)
ymn108 Cancer	West China Hospital	P1	CC (43)
Zamzetoclax Cancer	Gilead Sciences	P1	CC (43)
zw171 Cancer	Zymeworks BC Inc.	P1	CC (43)
αPD1-MSLN-CAR T cells Cancer	Shanghai Cell Therapy Group Co.,Ltd	P1/2	CC (43)
4H-Pyrido[1,2-a]pyrimidine-2-carboxamide, N-[[2-[[(cyclobutylmethyl)amino]methyl]-1H-indol-6-yl]methyl]-4-oxo- Cancer	STORM Therapeutics LTD	P1	CC (42)
Agen1777 Cancer	Agenus Inc.	P1	CC (42)
art4215 Cancer	Artios Pharma Ltd	P1	CC (42)
Bms-986213 Cancer	Bristol-Myers Squibb	P1/2	CC (42)
Bms-986408 Cancer	Bristol-Myers Squibb	P1/2	CC (42)
Bosutinib Cancer	Canadian Cancer Trials Group	P2	CC (42)
Budigalimab Cancer	AbbVie	P1	CC (42)
Camonsertib Cancer	Debiopharm International SA	P1/2	CC (42)
Dynamos Cancer	Turning Point Therapeutics, Inc.	P1	CC (42)
Elraglusib Cancer	Actuate Therapeutics Inc.	P2	CC (42)
Fapi-46 Cancer	Eben Rosenthal	P1	CC (42)
Fosifloxuridine Nafalbenamide Cancer	NuCana plc	P1/2	CC (42)
ibi321 Cancer	Innovent Biologics (Suzhou) Co. Ltd.	P1	CC (42)
ibi334 Cancer	Innovent Biologics (Suzhou) Co. Ltd.	P1/2	CC (42)
Immunoglobulin G1 [234-Alanine,235-Glutamic Acid,237-Alanine,330-Serine,331-Serine], Anti-(Human C5A Anaphylatoxin Chemotactic Receptor 1) (Human Monoclonal Tj210001 ?1-Chain), Disulfide With Human Monoclonal Tj210001 ?-Chain, Dimer Cancer	I-Mab Biopharma US Limited	P1	CC (42)
Immunoglobulin G1, Anti-(Human Interleukin-1 Receptor Accessory Protein) (Human-Mus Musculus Monoclonal Can04 .Gamma.1-Chain), Disulfide With Human-Mus Musculus Monoclonal Can04 .Kappa.-Chain, Dimer Cancer	Cantargia AB	P1/2	CC (42)

Showing 451 to 500 of 1,379 assets

PreviousPage 10 of 28Next